CEDAR KNOLLS, N.J.,
April 18, 2017 /PRNewswire/
-- MYOS RENS Technology Inc. (NASDAQ: MYOS) has entered into
an agreement with the College of Veterinary Medicine at
Kansas State University to study the
impact of Fortetropin® on reducing muscle loss in dogs after
ligament tear repair surgery. The study continues the
Company's investment in research regarding the therapeutic
potential of Fortetropin® across many broad areas of muscle
health.
"The rationale for pursuing this study with Kansas State is two-fold," commented Joseph Mannello, Interim Chief Executive Officer
of MYOS RENS. "One of our goals is to evaluate Fortetropin®'s
potential to improve musculoskeletal health in dogs. A
positive result could lay the foundation for the creation of a
companion animal (pet) nutrition business focused on
musculoskeletal health. This could have a substantial benefit
to MYOS RENS since the global animal health market, now at about
$35 billion, is projected to reach
$44.2 billion by 2020. Positive
results from this study would also lead to testing and developing
Fortetropin®-based products to aid humans recovering from
musculoskeletal surgeries. If Fortetropin® supplementation in
humans can reduce hospital stays or rehabilitation time by even one
day, the savings in healthcare costs could be substantial."
Fortetropin® is the company's flagship functional food
product. It is the first natural, clinically proven
myostatin-reducing ingredient made for human consumption and was
recently brought to market in the Qurr muscle health product line.
Qurr's Fortetropin® acts to build lean muscle mass and improve
strength and endurance. Qurr muscle health products can be
purchased at Qurr.com.
This veterinary research study is designed to investigate the
impact of Fortetropin® on reducing muscle atrophy in dogs after
TPLO (tibial-plateau-leveling osteotomy) surgery. TPLO
surgery is a common surgery performed in large dogs such as
Labrador Retrievers to stabilize the stifle joint after ruptures of
the CCL (cranial cruciate ligament), which is analogous to the ACL
(anterior cruciate ligament) in humans. MYOS RENS anticipates
the clinical study will be completed and its results announced in
the second quarter of 2018.
Dr. Neerav D. Padliya, Vice
President, Research Alliances of MYOS RENS, said, "We are excited
to be working with the College of Veterinary Medicine at
Kansas State University, one of the
leading veterinary colleges in the U.S., to explore the utility of
Fortetropin® in animal health for the first time. Reducing
muscle atrophy in dogs following orthopedic surgery is an area of
unmet need."
Kenneth R. Harkin, DVM, Diplomate
ACVIM (SAIM), and Hodes Professor of Internal Medicine at
Kansas State University, said "My
colleagues and I are excited about this collaboration with MYOS
RENS. Rehabilitation after TPLO surgery, essentially
increasing the muscle mass that stabilizes the cruciate deficient
knee, has been shown to improve mobility and decrease arthritic
changes. Fortetropin®, by naturally reducing myostatin levels,
offers an innovative approach to rehabilitation that is convenient
and accessible to all pet owners. We hope this will be the first of
many studies that evaluate the potential benefits of Fortetropin®
in companion animals."
About MYOS RENS Technology Inc.
MYOS RENS Technology
(MYOS), "The Muscle Company™", is a Cedar
Knolls, NJ-based biotherapeutics and bionutrition company
focused on developing products that improve muscle health and
performance and brings them to market. MYOS is the owner of
Fortetropin®, the world's first clinically demonstrated myostatin
reducer (myostatin is a natural regulatory protein, which inhibits
muscle growth). Fortetropin® is manufactured through a proprietary
process which retains its biological activity. MYOS believes
that Fortetropin® has the potential to redefine existing standards
of physical health and wellness enhancement and recently launched
the Qurr product line (Qurr.com), the Company's
newly-branded line of muscle health products geared to specific
demographics. For more information on MYOS and its proprietary
ingredient, Fortetropin®, visit www.myosrens.com.
Forward-Looking Statements
Any statements in this
release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
(including pet products) through research and development
(including the research described herein), the successful launch of
our products, including Qurr products, the success of our research
and development (including the research described herein), the
results of the clinical evaluation of Fortetropin® and its effects,
the ability to enter into partnership opportunities, the ability to
generate the forecasted revenue stream and cash flow from sales of
our products, the ability to achieve a sustainable, profitable
business, the effect of economic conditions, the ability to protect
our intellectual property rights, competition from other providers
and products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to update
or revise any forward-looking statement for events or circumstances
after the date on which such statement is made except as required
by law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure, or prevent any disease.
MYOS RENS Investor and Media Contact:
MYOS RENS Technology Inc.
Joanne Goodford
(973) 509-0444
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/myos-rens-enters-into-agreement-with-kansas-state-university-to-study-impact-of-fortetropin-on-reducing-muscle-loss-in-dogs-after-joint-surgery-300440429.html
SOURCE MYOS RENS Technology